Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Centre Léon Bérard
Lyon, France
Armelle Vinceneux, MDRecruiting - Gustave Roussy Cancer Institute
Villejuif, France
Yohann Loriot, MDRecruiting
- Massachusetts General Hospital - Boston
Boston, Massachusetts, United States
Leon Pappas, MDRecruiting - John Theurer Cancer Center
Hackensack, New Jersey, United States
Martin Gutierrez, MDRecruiting - Mount Sinai Tisch Cancer Center
New York, New York, United States
Thomas Marron, MDRecruiting - Next Oncology - Dallas
Dallas, Texas, United States
Recruiting - Next Oncology - Virginia
Fairfax, Virginia, United States
Recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 24 Jan 2025
- Primary completion
- 30 Apr 2028
- Completion
- 30 Apr 2029
- Last update posted
- 7 Jan 2026
- Registered enrollment
- 145
- Registry id
- NCT06781983
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.